SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2004
Savient Pharmaceuticals, Inc.
(Exact name of issuer as specified in its charter)
Delaware |
| 0-15313 |
| 13-3033811 |
(State or Other Jurisdiction |
| (Commission File Number) |
| (IRS Employer |
|
|
|
|
|
One Tower Center, 14th Floor |
| 08816 | ||
(Address of Principal Executive Offices) |
| (Zip Code) | ||
|
|
|
|
|
Registrant’s telephone number, including area code: (732) 418-9300 | ||||
|
|
|
|
|
None. | ||||
(Former Name or Former Address, if Changed Since Last Report.) | ||||
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 Transcript of the conference call discussing Savient Pharmaceuticals, Inc.’s earnings results for the three months and year ended December 31, 2003 held on February 20, 2004.
ITEM 9. REGULATION FD DISCLOSURE.
Filed herewith as Exhibit 99.1 is a transcript of the conference call discussing Savient Pharmaceuticals, Inc.’s earnings results for the three months and year ended December 31, 2003 held on February 20, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| SAVIENT PHARMACEUTICALS, INC. | |||
| (Registrant) | |||
|
|
|
| |
|
|
|
| |
| By: | /s/ Sim Fass |
| |
|
| Sim Fass | ||
|
| Chief Executive Officer | ||
|
|
|
| |
|
|
|
| |
Dated: February 20, 2004 |
|
|
| |
3
